MoonLake Immunotherapeutics MLTX Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's operating lease liabilities (total)?
- MoonLake Immunotherapeutics (MLTX) reported operating lease liabilities (total) of $1.79M in Q1 2026.
- How has MoonLake Immunotherapeutics's operating lease liabilities (total) changed year-over-year?
- MoonLake Immunotherapeutics's operating lease liabilities (total) decreased by 30.7% year-over-year, from $2.57M to $1.79M.
- What is the long-term trend for MoonLake Immunotherapeutics's operating lease liabilities (total)?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's operating lease liabilities (total) has grown at a 38.7% compound annual growth rate (CAGR), from $435.01K to $1.61M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.